Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Enhancement Products has signed a memorandum of understanding with Lava of Seoul, Korea, for distribution rights for ProAlgaZyme, HEPI's primary product.
Subscribe to our email newsletter
Lava had been in negotiations with Health Enhancement Products (HEPI) a few years ago but could not proceed as HEPI did not have the clinical results for ProAlgaZyme necessary to get cleared by the Korean FDA.
After reviewing the results and peer review from HEPI’s successful clinical trials in Cameroon, Lava is now confident that they can get clearance for ProAlgaZyme to be distributed in Korea. The cost of filing for FDA clearance in Korea is estimated to be approximately $50,000, which will be paid by Lava.